T-cell based dengue vaccine PRAHR wins best innovation award at GBU-Biothon

3 hours ago 2

dengue vaccine PRAHR, dengue vaccine, PRAHR, Gujarat Biotechnology University, Ahmedabad news, Gujarat news, India news, Indian express, existent   affairsSudhir Vaid, Chairman and MD, Concord Biotech; Prof Sir Peter Mathieson, Principal and V-C of the University of Edinburgh Scotland; and Mona K Khandhar, Principal Secretary, DST, presenting the award.

A TEAM of researchers astatine Gujarat Biotechnology University (GBU) Gandhinagar has developed an innovation of engineered T cell-based vaccine for dengue-Pathogen ReActive cells Harnessing T compartment receptors (TCRs) – PRAHR — which has bagged the ‘Best Societal Impact Award’ astatine the archetypal Biothon 2025 held connected January 20 astatine GBU. The squad led by Dr Ritesh Kumar Assistant Professor GBU Gandhinagar developed a caller vaccine conception to combat dengue, a large nationalist wellness interest successful tropical nations similar India. This vaccine focuses connected harnessing the body’s T cells—immune warriors—to destruct dengue-infected cells without triggering harmful immune responses.

“Unlike existing vaccines, which tin sometimes worsen dengue infections upon consequent exposure, this attack bypasses the hazard of antibody-dependent enhancement (ADE), a complication associated with accepted vaccines. By engineering T cells to admit and destruct infected cells, the vaccine offers a safer and much effectual solution,” Dr Ritesh Kumar mentoring the task told The Indian Express.

Researchers judge the innovative thought holds immense committedness for tackling a wide scope of diseases including cancer done cutting-edge immunoengineering technologies.

Dengue virus, which is the causative cause of dengue fever transmitted by Aedes mosquitoes, infects cells of immune strategy namely dendritic cells and macrophages. Most individuals infected, retrieve with small to nary complications and make important immunity against the infecting viral serotype.

“However, erstwhile exposed to different serotype of the microorganism (dengue microorganism has 4 serotypes, DENV 1-4) these individuals are astatine an accrued hazard of processing terrible disease, a information that clinicians telephone antibody-dependent illness enhancement oregon ADE. The archetypal lawsuit of viral infection, usually by a azygous serotype, culminates successful the secretion of antibodies by B-cell activation, and the eventual elimination of the microorganism from the system. Thus, rendering the idiosyncratic immune to the serotype encountered,” explains Dr Kumar.

Festive offer

Prof Rakesh Rawal, caput of section Medical Biotechnology GBU told this paper, “A large complication arises astatine the clip of 2nd corruption by different serotype, erstwhile antibodies generated successful the archetypal lawsuit hindrance to viral antigens with a overmuch little affinity. The beingness of these “low affinity” antibodies prevents clearance of the microorganism by agglutination and increases their uptake by immune cells possessing frankincense expanding the viral uptake and severity of infection.”

Further adding, Prof Rawal said, “Secondary dengue infections are often associated with pneumonia and death…Currently, determination are lone 2 dengue vaccines disposable and some being unrecorded vaccines person large information concerns associated with their use…”

To place potent TCR sequences, the radical of 4 students-Nachiket Waman, Tanish Kumar, Karishma Mistry, Achal Nawghade-combined multi-serotype viral antigen recognition with affinity-based enrichment of reactive T cells obtained from individuals with superior infection.

“The radical ideated a caller and unsocial attack to tackle a large wellness interest by employing cutting-edge immunoengineering technologies and impressed the sheet of manufacture experts judging the event. Thus, winning america the Award for Best Societal Impact astatine Biothon 2025,” Nachiket Waman, carnal biotechnology postgraduate pupil said.

Discover the Benefits of Our Subscription!

Stay informed with entree to our award-winning journalism.

Avoid misinformation with trusted, close reporting.

Make smarter decisions with insights that matter.

Choose your subscription package

© The Indian Express Pvt Ltd

*** Disclaimer: This Article is auto-aggregated by a Rss Api Program and has not been created or edited by Nandigram Times

(Note: This is an unedited and auto-generated story from Syndicated News Rss Api. News.nandigramtimes.com Staff may not have modified or edited the content body.

Please visit the Source Website that deserves the credit and responsibility for creating this content.)

Watch Live | Source Article